CHOICE OF TREATMENT IN PATIENTS WITH COMBINED PROSTATE INTRAEPITHELIAL NEOPLASIA OF PERIPHERIC AND CENTRAL ZONES

Authors:

Abstract:

The article deals with the problem of prostate intraepithelial neoplasia treatment as a precancerous state. Data of treatment results of 130 patients with prostate intraepithelial neoplasia of peripheric and central zones are analysed. Patients were distributed to groups depending on treatment method: active surveillance, Dutasteride treatment, transurethral prostate resection, and a combination of Dutasteride and transurethral prostate resection. Results were assessed after 3 years of follow-up by detecting of prostate cancer incidence. It was determined that in the active surveillance group prostate cancer rate was 68.8 %. Treatment in patients with prostate intraepithelial neoplasia of peripheric and central zones with Dutasteride decreased prostate cancer rate by 53.8 %, transurethral prostate resection decreased prostate cancer rate by 55.5 % and a combination of Dutasteride and transurethral prostate resection decreased prostate cancer rate by 54.5 %. Obtained data demonstrate the effectiveness of prostate cancer chemoprevention by prostate intraepithelial neoplasia treatment.

Keywords:

prostate intraepithelial neoplasia Dutasteride transurethral prostate resection

References:

1. Vilhova O. Suchasni pohlyady na histologichni osoblyvosti cholovichoyi statevoyi systemy World of Medicine and Biology. 2017;1(59):186–191]. [in Ukrainian]
2. Attard G, Parker C, Eeles R. Prostate cancer. Lancet. 2016; 387:70–82. doi.org/10.1016/S0140-6736(14)61947-4.
3. Bastarós J, Placer J, Celma A, Planas J, Morote J. Current significance of the finding of high grade prostatic intraepithelial neoplasia in the prostate biopsy. Actas Urol Esp. 2014 38(4); 270–5. doi: 10.1016/j.acuro.2013.10.001.
4. Bosland M. Is there a future for chemoprevention of prostate cancer. Cancer Prevention Research. 2016; 10:1940–6. doi: 10.1158/1940-6207.
5. Culp M, Soerjomataram I, Efstatiou J, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2019; 4: 2832–8. doi: 10.1016/j.eururo.2019.08.005.
6. Kang C, Xiangnan Li, Yabing Du, Xiance T, Seiji A, Yiwei G, Ying Xi. Chemoprevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia (HGPIN): a systematic review and adjusted indirect treatment comparison. Oncotarget. 2017; 8 (22): 36674–84. doi: 10.18632/oncotarget.16230.
7. Luis B, Amar SA, Holly S, Sakunthala K, Geraldine S, Henrik M, et al. Histopathologic False-positive Diagnoses of Prostate Cancer in the Age of Immunohistochemistry 1 3; Transatlantic Prostate Group. Am J Surg Pathol 2019 Mar;43(3):361–368. doi: 10.1097/PAS.0000000000001202.
8. Milonas D, Auskalnis S, Skulcius G, Gudinaviciene I, Jievaltas M, Joniau S. Dutasteride for the prevention of prostate cancer in men with high-grade prostatic intraepithelial neoplasia: results of a phase III randomized open-label 3-year trial. World J Urol. 2017; 35:721–728. doi: 10.1007/s00345-016-1938-8
9. Mohanty P, Nanda A, Mohanty L.Indian J Histomorphological study of prostatic adenocarcinoma and its mimics. Pathol Microbiol. 2019; 62(2):251–260. doi: 10.4103/IJPM.IJPM_322_18.
10. Montironi R, Modena A, Ciccarese C, Iacovelli R, Brunelli M, Fiorentino M. Immune Checkpoint Inhibitors and Prostate Cancer: A New Frontier? Oncol Rev. 2016; 10:287–93. doi: 10.4081/oncol.2016.293.
11. Montironi R, Zhou M, Magi-Galuzzi C, Epstein J Features and prognostic significance of intraductal carcinoma of the prostate. Eur Urol Oncol. 2018; 1:21-8. doi: 10.1016/j.euo.2018.03.013.
12. Nakay Y, Tanaka N, Miyake M, Hori S, Tatsumi Y, Morizawa Y, et al. Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume. Res Rep Urol. 2017; 21: 187–93. doi: 10.2147/RRU.S148424.
13. Patel P, Nayak J, Biljetina Z, Donelly B, Trpkov K. Prostate cancer after initial high-grade prostatic intraepithelial neoplasia and benign prostate biopsy. Can J Urol. 2015; 22 (6): 8056–62. PMID: 26688133.
14. Schwartzmann I, Celma A, Gallardo I, Moreno O, Regis L, Placer J, et al. In Search for risk predictors at the microscopic scenario of a negative biopsy. A systematic review. Actas Urol Esp. 2019; 43(7): 337–47. doi: 10.1016/j.acuro.2019.01.010.
15. Varghese J, Kuruvilla P, Mehta N, Rathore R, Babu M, Bansal D, et al. Incidentally Detected Adenocarcinoma Prostate in Transurethral Resection of Prostate Specimens: a Hospital Based Study from India. Asian Pac J Cander Prev. 2016; 17 (4):2255–8. doi:10.7314/apjcp.2016.17.4.2255.

Publication:

«World of Medicine and Biology» Vol. 19 No. 84 (2023) , с. 105-108
УДК 616.65-006.6-089

DOI:

https://doi.org/10.26724/2079-8334-2023-2-84-105-108